Logo

PreludeDx: Derek Maetzold

Feb 07, 2022

PreludeDx has appointed Derek Maetzold to its board of directors. Maetzold founded Castle Biosciences, serving as president, CEO, and a board member since its inception in 2007. He co-invented several Castle technologies and has contributed to the development and commercialization of five diagnostic and prognostic cancer tests.

Prior to Castle, Maetzold spent 24 years in pharma, holding leadership roles at Encysive Pharmaceuticals (acquired by Pfizer), Schering-Plough Corporation (now Merck), Integrated Communications (now FCB Health), Amylin Pharmaceuticals (now owned by AstraZeneca), and Sandoz Pharmaceuticals (now a division of Novartis).

Breaking News
The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.